MIRA Pharmaceuticals jumps as oral pain drug beats morphine in animal study

Mira Pharmaceuticals

16/10/2025 12:08

** Shares of drug developer MIRA Pharmaceuticals MIRA.O rise 90% to $2.52 premarket

** Company says its experimental oral drug, Mira-55, eased pain and reduced swelling better than injected morphine in a pre-clinical animal study for chronic inflammatory pain

** Mira-55 brought pain levels back to normal and directly reduced inflammation by targeting the CB2 receptor - MIRA

** CB2 receptors are expressed in immune cells and are involved in the regulation of immune responses and inflammation

** Company says morphine only partially reduced inflammation

** Data supports marketing application plans for Mira-55 for chronic inflammatory pain - MIRA

** Up to last close, shares up ~16% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.pandey@thomsonreuters.com))